Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
about
Brain PET in the diagnosis of Alzheimer's disease18F-florbetaben Aβ imaging in mild cognitive impairmentAdvances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.Future Directions in Imaging Neurodegeneration.Communicating mild cognitive impairment diagnoses with and without amyloid imaging.Positron emission tomography radioligands for in vivo imaging of Aβ plaques.Radiosyntheses using fluorine-18: the art and science of late stage fluorinationArterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions.Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer diseaseA survey of FDG- and amyloid-PET imaging in dementia and GRADE analysisIn vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamolAmyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomographyAmyloid imaging in the differential diagnosis of dementia: review and potential clinical applications.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's AssociationAmyloid-β positron emission tomography imaging probes: a critical review.Amyloid deposition and cognition in older adults: the effects of premorbid intellect.Amyloid imaging in atypical presentations of Alzheimer's disease.Cerebral amyloid PET imaging in Alzheimer's disease.Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β-amyloid PET brain images.Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.Amyloid imaging in Alzheimer's disease: a literature review.Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.Filling the void: a role for exercise induced BDNF and brain amyloid precursor protein processing.A new integrated dual time-point amyloid PET/MRI data analysis method.Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers.Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.
P2860
Q27011549-A8F4CEB3-B0FD-46C1-9C5E-B9A9C48064BCQ27499311-B6E32D68-374B-4CEE-8AD8-13784A5D57D3Q30945416-562949D3-CF05-4C1E-85CA-FB2F91DDBA6AQ31162702-031676B7-12E0-449C-AC1B-6B4287976DB5Q33640373-73A65B91-A0D2-4C96-92EE-CF8448592946Q33874024-0FF0A762-F0CF-4EC2-ADBE-1718951F69D6Q34074437-3F8E9B22-C56D-4C54-9171-3B6A66BD5B55Q34275490-A9D6AF36-B86C-4AA4-B211-3290457BE6DAQ34423050-BB90DE64-F4E8-4F34-9DB5-AD7652C34E64Q34493453-9AC965C3-03C1-4EE4-AAFD-1F8BE9E4BA3AQ35158547-B8790F71-3C28-4295-A857-674F862B0640Q35546528-E9081C29-42D9-4F4D-81FF-CB12DDE85AD6Q35603195-BF148AD5-897B-478C-A654-CA30A9DA0C91Q35777166-3AAC50E5-019B-4A79-81EC-5B7B904515AAQ35840614-7D3F9B77-581C-4D55-A115-8DA9BE6FC9B5Q35840623-AAF616AC-FA2B-4554-957E-993521AA392FQ36250470-C144FEF7-9A4F-4833-92AD-CEA5EC164DE9Q36267484-13E484B1-9799-4A4E-9F67-12ECD5585A7FQ36526176-781A6627-3167-4F97-A24C-F67AC27997ACQ36639655-EEB02A7E-DFDC-4DED-9F84-0F4A47FC41A6Q37069527-4C114F60-051C-44E9-961F-8EFF7DC9F5A1Q37086266-4BA86B20-6027-43E7-80D8-11BDF9A18078Q37254106-2AFC55AF-6759-4714-8954-87AF16C0B245Q37393266-346F34A9-1A9C-452D-B5AF-B847DE5075F7Q37459083-F5204114-005E-498A-B246-9B5B31DF0FFAQ37498339-6D522622-0598-40FB-BDC7-7C55D50DA342Q37605374-F944334B-0E4E-402D-AD3D-64EDCC18E970Q37653198-077F4002-7C53-41B2-955D-69540C678DC3Q37703254-71EB93DB-D365-4698-B701-F82F289B2E3AQ37730221-D92D6C82-73BF-41D9-9A36-6504ECD38E91Q38219529-24AD59F6-7708-49ED-8178-D4FB42C08C5AQ38250091-557085EE-2FD9-4B77-9F54-E84AA0C00120Q38368611-F30CFC2A-7826-49AE-8686-36D110441D90Q38600277-62428DE3-CA71-47CF-8E5C-DE6816B10433Q38641542-3FF629CC-54C0-4565-B6EC-C72D20E9AFB9Q38694948-8D9827FE-187C-4684-9E68-F1F47A3DBAB0Q38903262-39CC9E15-5DDA-43DE-9DCC-6D5834F3BC92Q39451611-C4BE1C77-77F3-4944-AA33-1B36515B7662Q39529635-79263F8D-4D15-44F2-B23E-3B08CDDD4BC2Q40600414-21BB2C9B-8B47-4B84-9034-EB01FB36564D
P2860
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Association between in vivo fl ...... ebral cortical histopathology.
@ast
Association between in vivo fl ...... ebral cortical histopathology.
@en
type
label
Association between in vivo fl ...... ebral cortical histopathology.
@ast
Association between in vivo fl ...... ebral cortical histopathology.
@en
prefLabel
Association between in vivo fl ...... ebral cortical histopathology.
@ast
Association between in vivo fl ...... ebral cortical histopathology.
@en
P2093
P2860
P1433
P1476
Association between in vivo fl ...... ebral cortical histopathology.
@en
P2093
Chris Buckley
David A Wolk
Igor D Grachev
M Sean Grady
Paul Sherwin
Richard McLain
Roy H Hamilton
P2860
P304
P356
10.1001/ARCHNEUROL.2011.153
P577
2011-07-11T00:00:00Z